



## **Bio-Path Holdings to Announce Second Quarter 2022 Financial Results on August 16, 2022**

**HOUSTON – August 9, 2022** – Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Tuesday, August 16, 2022 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2022 and to provide a business overview.

To access the live conference call, please call (833) 630-1956 (domestic) or (412) 317-1837 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the Presentations section of the Company's website, [www.biopathholdings.com](http://www.biopathholdings.com). An archived webcast will be available on the Bio-Path website approximately two hours after the event.

### **About Bio-Path Holdings, Inc.**

Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path's lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and BP1001-A, a drug product modification of prexigebersen, has been cleared by the FDA and Phase 1 studies in solid tumors will commence in 2022. The Company's second product BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. In addition, an IND is expected to be filed for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3, in 2022 or first quarter 2023.

For more information, please visit the Company's website at <http://www.biopathholdings.com>.

###

### **Contact Information:**

**Investors**

Will O'Connor  
Stern Investor Relations  
212-362-1200  
[will@sternir.com](mailto:will@sternir.com)

Doug Morris  
Investor Relations  
Bio-Path Holdings, Inc.  
832-742-1369